| http://www.w3.org/ns/prov#value | - GPhA's independent analysis raises serious questions about the validity of the recent PhRMA study on authorized generics, noting that factors such as an inconsistent choice of data, inadequate data points and the use of wholesale instead of retail prices resulted in "significant problems" and that the errors create great concerns regarding the utility of the conclusions provided by it.
|
